Therapeutic approaches for corneal neovascularization

被引:0
作者
Sepehr Feizi
Amir A. Azari
Sharareh Safapour
机构
[1] Shahid Beheshti University of Medical Sciences,Ophthalmic Research Center, Labbafinejad Medical Center
来源
Eye and Vision | / 4卷
关键词
Corneal neovascularization; Angiogenesis; Angiogenic therapies;
D O I
暂无
中图分类号
学科分类号
摘要
Angiogenesis refers to new blood vessels that originate from pre-existing vascular structures. Corneal neovascularization which can lead to compromised visual acuity occurs in a wide variety of corneal pathologies. A large subset of measures has been advocated to prevent and/or treat corneal neovascularization with varying degrees of success. These approaches include topical corticosteroid administration, laser treatment, cautery, and fine needle diathermy. Since the imbalance between proangiogenic agents and antiangiogenic agents primarily mediate the process of corneal neovascularization, recent therapies are intended to disrupt the different steps in the synthesis and actions of proangiogenic factors. These approaches, however, are only partially effective and may lead to several side effects. The aim of this article is to review the most relevant treatments for corneal neovascularization available so far.
引用
收藏
相关论文
共 525 条
  • [21] Panda A(2004)VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment J Clin Invest 113 1040-1050
  • [22] Vanathi M(2009)Treating age-related macular degeneration-interaction of VEGF-antagonists with their target Mini Rev Med Chem 9 1127-1135
  • [23] Kumar A(2007)Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis FASEB J 21 1003-1012
  • [24] Dash Y(2011)Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies Genes Cancer. 2 1097-105
  • [25] Priya S(1999)Effect of PDGF, IL-1alpha, and BMP2/4 on corneal fibroblast chemotaxis: expression of the platelet-derived growth factor system in the cornea Invest Ophthalmol Vis Sci 40 1364-1372
  • [26] Sellami D(1993)Platelet-derived growth factor: receptor expression in corneas and effects on corneal cells Invest Ophthalmol Vis Sci 34 637-649
  • [27] Abid S(2010)Novel aspects of corneal angiogenic and lymphangiogenic privilege Prog Retin Eye Res 29 208-248
  • [28] Bouaouaja G(2009)Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist Invest Ophthalmol Vis Sci 50 4761-4768
  • [29] Ben Amor S(1997)Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 277-285
  • [30] Kammoun B(2006)Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis) Trans Am Ophthalmol Soc 104 264-302